In the just concluded week, Auris Medical Holding Ltd. (EARS) made the biggest weekly advance, gaining over 180%, thanks to positive in vitro efficacy data of AM-301 in protecting against SARS-CoV-2 infection.
A couple of stocks, say, Merrimack Pharmaceuticals Inc. (MACK), Codiak BioSciences Inc. (CDAK), Salarius Pharmaceuticals Inc. (SLRX), and Cellectar Biosciences Inc. (CLRB) registered gains in excess of 50% for the week.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com